The short version of reference standard fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-30. Anything still debated is marked as such rather than presented as settled.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
This would reduce the physical bandwidth requirements by 2–3×, placing it well within the capabilities of an HBR2-rated cable. This exemplifies why DisplayPort cables are not classified by "version"; although DSC was introduced in version 1.4, this does not mean it needs a so-called "DP 1.4 cable" (an HBR3-rated cable) to function. HBR3 cables are only required for applications which exceed HBR2-level bandwidth, not simply any application involving DisplayPort 1.4. If DSC is used to reduce the bandwidth requirements to HBR2 levels, then an HBR2-rated cable will be sufficient. In version 2.1, VESA introduced the DP40 and DP80 cable certification tiers, which validate cables for UHBR10 and UHBR20 speeds respectively. DisplayPort 2.1a introduced DP54 cable certification for UHBR13.5 speed.
== Nearby points of interest == Gypsy Cove, known for its Magellanic penguins, and Cape Pembroke, the easternmost point of the Falklands, lie nearby. Gypsy Cove is four miles (6 km) from Stanley and can be reached by taxi or on foot.
=== Organizations === Professional organizations such as the Androgen Excess and PCOS Society exist to promote the research, treatment, diagnosis, and prevention of such disorders and to educate the public and scientific community about them. InterACT, an intersex organization, listed hyperandrogenism as an intersex variation in a glossary from 2022.
Sources: en.wikipedia.org
== Treatment == CTD is difficult to treat because the transporter responsible for transporting creatine to the brain and muscles is defective. Affected individuals have sufficient amounts of creatine, but it cannot get to the tissues where it is needed. Studies in which oral creatine monohydrate supplements were given to patients with CTD found that patients did not respond to treatment. Patients with CTD are unresponsive to oral creatine monohydrate supplements because regardless of the amount of creatine they ingest, the creatine transporter is still defective, and therefore creatine is incapable of being transported across the BBB. Therapeutic approaches that are currently in development include dodecyl creatine ester (DCE) for intranasal creatine delivery, pharmacochaperones to aid in rescuing misfolded transporter, and gene therapy to compensate for the mutated SLC6A8 gene.
Mariusz Zbigniew Pudzianowski (Polish pronunciation: [ˈmarjuʂ pudʑaˈnɔfskʲi]; born 7 February 1977), also known as 'Pudzian' and 'Dominator', is a Polish former strongman and mixed martial artist. With 43 international titles at a record 70% win percentage, 58 total wins, 71 podiums and 28 world records in his strongman career. During his career as a strongman, Pudzianowski won five World's Strongest Man titles in 2002, 2003, 2005, 2007 and 2008, the most in the 48 year history of the competition. He also won two runner-up titles in 2006 and 2009 and made 9 out of 9 appearances into the World's Strongest Man final (a feat replicated only by Hafþór Júlíus Björnsson since then). While securing eight World Strongman Cup Federation wins and twelve Strongman Super Series wins, he also won the Europe's Strongest Man title a record six times and the Poland's Strongest Man title a record seven times. In 2009, Pudzianowski started his career as a mixed martial artist. By 2022, he had won his 17th professional fight.
===== Erection angle ===== Although many erect penises point upwards, it is common and normal for erect penis to curve in any direction. Many penises are curved in right, left, upwards or downwards direction depending upon the tension of the suspensory ligament that holds it in position. The following table shows how common various erection angles are for a standing male, out of a sample of 81 males aged 21 through 67. In the table, zero degrees is pointing straight up against the abdomen, 90 degrees is horizontal and pointing straight forward, while 180 degrees would be pointing straight down to the feet. An upward pointing angle is most common.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.